Stock Ratings | Potential Upside of 284.62%! Leerink Partners initiated coverage of Ovid Therapeutics (OVID) with an "Outperform" rating and a $5 price target.
Sahm Platform 18/11 01:42
Morgan Stanley Reiterates Overweight on Palo Alto Networks, Maintains $360 Price Target
Palo Alto Networks, Inc. PANW | 0.00 |
